The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Rawan Faramand, MD, Moffitt Cancer Center, Tampa, FL, shares insights into the Phase III Precision-T trial (NCT05316701), which compared standard graft-versus-host disease (GvHD) prevention with tacrolimus-methotrexate to Orca-T, an investigational allogeneic T-cell product. Dr Faramand explains that Orca-T utilizes highly purified regulatory and conventional T-cells in a defined one-to-one ratio, aiming to improve immune reconstitution, reduce rates of severe chronic GVHD, and maintain graft-versus-leukemia effect. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
